The diagnosis of neuromuscular disorders, including SMA, in young children is often delayed, preventing patients from receiving the management and services they require.2
With treatment now available for SMA, its relative effectiveness may depend on being able to identify patients early enough to initiate treatment before irreversible neuronal loss occurs.1,3